1. Home
  2. English
  3. Business
  4. Torrent Pharma announces Q2 FY24 results, Branded markets continue to deliver strong growth
Torrent Pharma announces Q2 FY24 results, Branded markets continue to deliver strong growth

Torrent Pharma announces Q2 FY24 results, Branded markets continue to deliver strong growth

0
Social Share

Ahmedabad, October 23, 2023:  

India: 

  • India revenue at Rs 1,444 crores grew by 18% 
  • As per AIOCD secondary market data, IPM growth for the quarter was 4%. Market outperformance was led by continued double digit growth in chronic  therapies, revival in gastro demand, traction in consumer division, and new launches. Curatio portfolio grew by 17% led by strong growth in top focus brands. For H1 FY24, revenues were Rs 2,870 crores, up by 16%.  

Brazil: 

  • Brazil revenue at Rs 252 crores, was up by 36%.  
  • Constant currency revenue at R$ 149 million was up by 23%. Q2 revenues reflect the impact of  sales spillover from Q1.  
  • As per secondary data set, Torrent’s Q2 BGx growth is 13% versus BGx market growth of 8%.
  • Growth was aided by performance of top brands, new launches and growth in generic segmentFor H1 FY24, revenues were Rs 442 crores, up by 20% (Constant currency revenue: R$ 263 million, up by 11%).  

Germany: 

  • Germany revenue at Rs 266 crores was up by 21%.  
  • Constant currency revenue at Euro 30 million was up by 8%.  
  • Growth momentum continues with new tender wins coupled with better conversion of existing tenders. 
  • For H1 FY24, revenues were Rs 525 crores, up by 21% (Constant currency revenue: Euro  58 million, up by 9%).  

United States: 

  • US revenue at Rs 248 crores, was down by 15%. 
  • Constant currency revenue at $30 million was down by 18%. Adjusted for one off income in the corresponding quarter previous year, the de-growth is 13% (INR) & 16% (constant  currency) 
  • Growth was impacted by loss of low margin business and lack of new launches.  Dahej facility has received EIR which paves way for the new product approvals. As on September 30, 2023, 41 ANDAs were pending approval with USFDA and 3 tentative  approvals were received. During the quarter, 1 ANDA was approved. 
  • For H1 FY24, revenues were Rs 541 crores, down by 8% (Constant currency revenue: $66 million down by 13%). Adjusted for one off income, constant currency de-growth at 7%.  

LEAVE YOUR COMMENT

Your email address will not be published.

Join our WhatsApp Channel

And stay informed with the latest news and updates.

Join Now
revoi whats app qr code